03.06.2016 08:10:09
|
AstraZeneca Completes US Licensing Deal With Ironwood Pharma For Lesinurad
(RTTNews) - British drug maker AstraZeneca plc (AZN.L, AZN) announced Friday that it has completed the licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic (lesinurad) and the fixed-dose combination of lesinurad and allopurinol.
Zurampic is approved in the US, in combination with a xanthine oxidase inhibitor, for the treatment of hyperuricemia associated with uncontrolled gout.
The company said the fixed-dose combination will be submitted for regulatory review in the second half of 2016.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Ironwood Pharmaceuticals Inc (A)mehr Nachrichten
06.11.24 |
Ausblick: Ironwood Pharmaceuticals A vermeldet Zahlen zum jüngsten Quartal (finanzen.net) |
Analysen zu Ironwood Pharmaceuticals Inc (A)mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 71,50 | 0,70% |
|
Ironwood Pharmaceuticals Inc (A) | 1,71 | 2,40% |
|